Glass House Brands (GLAS) Cash from Financing Activities (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Cash from Financing Activities of $19.1 million for Q1 2026, up 288.08% year-over-year from $4.9 million in Q1 2025, and up 3619.93% quarter-over-quarter from -$542000.0 in Q4 2025.
Glass House Brands (GLAS) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Cash from Financing Activities for 7 consecutive years, with $19.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 288.08% year-over-year to $19.1 million; the TTM figure through Mar 2026 stood at $16.9 million (up 441.3% YoY), while the FY2025 annual figure was $2.7 million, up 119.87% from the prior year.
- Cash from Financing Activities advanced to $19.1 million in Q1 2026 per GLAS's latest filing, from -$542000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $8421.8 billion in Q3 2023 and bottomed at -$779.1 billion in Q4 2022.
- Historically, Cash from Financing Activities has averaged $449.6 billion across 5 years, with a median of $551000.0 in 2023.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities soared 100895742.82% — and 2024, when it tumbled 784.03%.
- Glass House Brands' Cash from Financing Activities stood at -$779.1 billion in 2022, then surged by 100.0% to $551000.0 in 2023, then sank by 784.03% to -$3.8 million in 2024, then surged by 85.62% to -$542000.0 in 2025, then soared by 3619.93% to $19.1 million in 2026.
- Business Quant data shows GLAS's Cash from Financing Activities at $19.1 million in Q1 2026, -$542000.0 in Q4 2025, and $231000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Glass House Brands | 837.25 Mn | 818.69 Mn | 15.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.08 Mn |
| Mar 31, 2026 | 19.08 Mn |
| Dec 31, 2025 | -542,000.00 |
| Dec 31, 2025 | -542,000.00 |
| Sep 30, 2025 | 231,000.00 |
| Sep 30, 2025 | 231,000.00 |
| Jun 30, 2025 | -1.88 Mn |
| Jun 30, 2025 | -1.88 Mn |
| Mar 31, 2025 | 4.92 Mn |
| Mar 31, 2025 | 4.92 Mn |
| Dec 31, 2024 | -3.77 Mn |
| Dec 31, 2024 | -3.77 Mn |
| Sep 30, 2024 | -2.58 Mn |
| Sep 30, 2024 | -2.58 Mn |
| Jun 30, 2024 | -3.52 Mn |
| Jun 30, 2024 | -3.52 Mn |
| Mar 31, 2024 | -3.84 Mn |
| Mar 31, 2024 | -3.84 Mn |
| Dec 31, 2023 | 551,000.00 |
| Dec 31, 2023 | 551,000.00 |